-
EP3785724
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3785724
| EP3785724 - GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 05.05.2023 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 10.09.2021 | ||
| Former | The application has been published Status updated on 29.01.2021 | Most recent event Tooltip | 02.07.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2021/09] | Inventor(s) | 01 /
Chen, Yanyun c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, IN 46206-6288 / US | 02 /
Mezo, Adam Robert c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, IN 46206-6288 / US | 03 /
Qu, Hongchang c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, IN 46206-6288 / US | 04 /
Valenzuela, Francisco Alcides c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, IN 46206-6288 / US | [2021/09] | Representative(s) | O'Connor, David, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [2021/09] | Application number, filing date | 20198508.2 | 16.06.2016 | [2021/09] | Priority number, date | US201562182847P | 22.06.2015 Original published format: US 201562182847 P | [2021/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3785724 | Date: | 03.03.2021 | Language: | EN | [2021/09] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 20.01.2021 | Classification | IPC: | A61K38/00, A61K38/26, C07K14/605, C07K14/00, A61P3/00, A61P1/00, A61P43/00, A61P3/04, A61P3/06, A61P3/10, A61P1/16 | [2021/09] | CPC: |
C07K14/605 (EP,CN,IL,KR,US);
C07K14/00 (EP,CN,IL,KR,US);
A61K38/00 (EP,CN,IL,KR,US);
A61K47/542 (CN);
A61K47/60 (CN);
A61K47/65 (CN);
A61P1/00 (EP,IL);
A61P1/16 (EP,CN,IL);
A61P3/00 (EP,IL);
A61P3/04 (EP,CN,IL);
A61P3/06 (EP,IL);
A61P3/10 (EP,CN,IL);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/41] |
| Former [2021/09] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Extension states | BA | 03.09.2021 | ME | 03.09.2021 | Validation states | MA | 03.09.2021 | MD | 03.09.2021 | Title | German: | GLUCAGON- UND GLP-1-CO-AGONIST-VERBINDUNGEN | [2021/09] | English: | GLUCAGON AND GLP-1 CO-AGONIST COMPOUNDS | [2021/09] | French: | COMPOSÉS DE CO-AGONISTES DU GLUCAGON ET DU GLP-1 | [2021/09] | Examination procedure | 03.09.2021 | Amendment by applicant (claims and/or description) | 03.09.2021 | Examination requested [2021/41] | 03.09.2021 | Date on which the examining division has become responsible | 04.05.2023 | Despatch of a communication from the examining division (Time limit: M06) | 06.11.2023 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP16733268.3 / EP3310371 | Fees paid | Renewal fee | 25.01.2021 | Renewal fee patent year 03 | 25.01.2021 | Renewal fee patent year 04 | 25.01.2021 | Renewal fee patent year 05 | 30.06.2021 | Renewal fee patent year 06 | 30.06.2022 | Renewal fee patent year 07 | 30.06.2023 | Renewal fee patent year 08 | 01.07.2024 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]CA2852177 (UNIV INDIANA RES & TECH CORP [US]) [I] 1-44 * examples 6,16; table 3; sequence 526 *; | [I]WO2011094337 (UNIV INDIANA RES & TECH CORP [US], et al) [I] 1-44 * paragraphs [0087] , [0099] , [00237] , [00290] , [00558]; claims 13-15,36,57,282,286; sequences 900, 901,908, 926 *; | [I]WO2013004983 (IMP INNOVATIONS LTD [GB], et al) [I] 1-44 * page 4, line 21 - page 9, line 26; sequences 1, 44 *; | [I]WO2013074910 (UNIV INDIANA RES & TECH CORP [US]) [I] 1-44 * paragraphs [0017] , [0195] , [00208] , [00377]; sequence 526 *; | [I]WO2014152460 (UNIV INDIANA RES & TECH CORP [US]) [I] 1-44 * page 46, line 5 - line 25; claim 1 * * page 115, line 20 - line 31 ** page 155, line 11 - line 33; sequence 1 * | by applicant | WO2011075393 | WO2012177444 | - HERMAN et al., Diabetes, (19940000), vol. 43, page 40 | - ZIMMET et al., Diabetes Med., (19940000), vol. 11, page 299 | - "Expert Committee on Classification of Diabetes Mellitus", Diabetes Care, (19990000), vol. 22, no. 1, page S5 | - CHARLES et al., Diabetes, (19910000), vol. 40, page 796 | - CHEMICAL ABSTRACTS, Database accession no. 910463-68-2 | - GRAZIANO MPHEY PJBORKOWSKI DCHICCHI GGSTRADER CD, Biochem Biophys Res Commun., (19930000), vol. 196, no. 1, pages 141 - 6 | - GRINNELL, B.W.BERG, D.T.WALLS, J.YAN, S.B., Bio/Technology, (19870000), vol. 5, pages 1189 - 1192 | - CHENG, Y.PRUSOFF, W. H., Biochem. Pharmacol., (19730000), vol. 22, pages 3099 - 3108 | - LOK, S, Gene, (19940000), vol. 140, no. 2, pages 203 - 209 |